UK Markets open in 3 hrs 30 mins
NIKKEI 225
28,967.94 +25.80 (+0.09%) HANG SENG
19,865.88 +101.97 (+0.52%) CRUDE OIL
90.09 -0.41 (-0.45%) GOLD FUTURES
1,769.20 -2.00 (-0.11%) DOW
33,999.04 +18.72 (+0.06%) BTC-GBP
19,125.55 -656.03 (-3.32%)
AstraZeneca PLC (AZN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 66.42 |
| Open | 66.76 |
| Bid | 66.51 x 3100 |
| Ask | 66.79 x 1100 |
| Day's range | 66.13 - 66.86 |
| 52-week range | 53.63 - 71.70 |
| Volume | |
| Avg. volume | 6,240,090 |
| Market cap | 206.07B |
| Beta (5Y monthly) | 0.10 |
| PE ratio (TTM) | 122.81 |
| EPS (TTM) | 0.54 |
| Earnings date | N/A |
| Forward dividend & yield | 1.44 (2.15%) |
| Ex-dividend date | 24 Feb 2022 |
| 1y target est | 72.70 |
- Zacks
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
- Zacks
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
- Business Wire
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
WILMINGTON, Del., August 16, 2022--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
© 2022 Yahoo. All rights reserved.
